$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924004234 Filed on February 15, 2024

Income Statement

Concept	2024 Q1	2023 Q3	2023
Revenue	$31.87K	$39.52K	$75.72K
YoY Change	91.34%	2417.2%	383.8%
Cost Of Revenue	$21.56K	$23.28K	$78.16K
YoY Change	15.16%	17807.69%	51.81%
Gross Profit	$10.31K	$16.24K	-$2.439K
YoY Change	-599.56%	1027.78%	-93.19%
Gross Profit Margin	32.36%	41.09%	-3.22%
Selling, General & Admin	$683.2K	$1.145M	$4.371M
YoY Change	-45.47%	-5.45%	-3.29%
% of Gross Profit	6625.78%	7053.02%
Research & Development	$203.9K	$199.8K	$670.9K
YoY Change	19.48%	-13.61%	-41.83%
% of Gross Profit	1977.2%	1229.99%
Depreciation & Amortization	$560.00	$1.970K	$1.966K
YoY Change	47.37%	146.25%	-38.49%
% of Gross Profit	5.43%	12.13%
Operating Expenses	$887.1K	$1.345M	$5.042M
YoY Change	-37.68%	-6.76%	-11.12%
Operating Profit	-$876.7K	-$1.329M	-$5.044M
YoY Change	-38.5%	-7.79%	-11.64%
Interest Expense	$592.4K	-$1.128M	$3.097M
YoY Change	-6.74%	152.2%	446.08%
% of Operating Profit
Other Income/Expense, Net	-$592.4K		-$1.938M
YoY Change	-213.27%		-547.71%
Pretax Income	-$1.469M	-$2.457M	-$6.983M
YoY Change	62.79%	30.11%	32.35%
Income Tax
% Of Pretax Income
Net Earnings	-$1.469M	-$2.457M	-$6.983M
YoY Change	62.79%	30.11%	32.35%
Net Earnings / Revenue	-4610.37%	-6217.61%	-9221.43%
Basic Earnings Per Share	-$0.33		-$2.27
Diluted Earnings Per Share	-$0.33	-$1.36	-$2.27
COMMON SHARES
Basic Shares Outstanding	4.742M	3.094M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.43K	$222.7K	$222.7K
YoY Change	-10.41%	-70.18%	-70.18%
Cash & Equivalents	$26.43K	$222.7K
Short-Term Investments
Other Short-Term Assets	$177.2K	$362.9K	$362.9K
YoY Change	13.31%	-16.85%	-16.85%
Inventory	$1.330M	$1.365M	$1.365M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.533M	$1.950M	$1.950M
YoY Change	-3.47%	-24.94%	-24.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.390K	$4.599K	$4.600K
YoY Change	238.66%	125.0%	125.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.500K	$3.500K	$3.500K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$6.890K	$8.099K	$8.100K
YoY Change	53.08%	46.09%	46.21%
TOTAL ASSETS
Total Short-Term Assets	$1.533M	$1.950M	$1.950M
Total Long-Term Assets	$6.890K	$8.099K	$8.100K
Total Assets	$1.540M	$1.958M	$1.958M
YoY Change	-3.31%	-24.79%	-24.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.970M	$2.304M	$2.304M
YoY Change	22.41%	73.51%	73.51%
Accrued Expenses	$1.390M	$1.291M	$1.291M
YoY Change	63.25%	189.19%	189.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.898M	$5.628M	$5.628M
YoY Change	55.51%	923.24%	923.24%
Total Short-Term Liabilities	$12.42M	$9.466M	$9.466M
YoY Change	55.63%	185.08%	185.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.42M	$9.466M	$9.466M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.42M	$9.466M	$9.466M
YoY Change	55.63%	39.28%	39.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.21M	-$62.06M
YoY Change	14.59%	12.68%
Common Stock	$55.33M	$54.55M
YoY Change	7.67%	7.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.88M	-$7.508M	-$7.508M
YoY Change
Total Liabilities & Shareholders Equity	$1.540M	$1.958M	$1.958M
YoY Change	-3.31%	-24.79%	-24.79%

Cashflow Statement

Concept	2024 Q1	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$1.469M	-$2.457M	-$6.983M
YoY Change	62.79%	30.11%	32.35%
Depreciation, Depletion And Amortization	$560.00	$1.970K	$1.966K
YoY Change	47.37%	146.25%	-38.49%
Cash From Operating Activities	-$700.1K	-$1.224M	-$3.374M
YoY Change	16.72%	-26.67%	-24.28%
INVESTING ACTIVITIES
Capital Expenditures		$4.520K	$4.521K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$4.520K	-$4.521K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	520.7K	1.365M	$2.855M
YoY Change	-15.84%	-42.22%	-2.79%
NET CHANGE
Cash From Operating Activities	-700.1K	-1.224M	-$3.374M
Cash From Investing Activities		-4.520K	-$4.521K
Cash From Financing Activities	520.7K	1.365M	$2.855M
Net Change In Cash	-179.4K	135.8K	-$524.2K
YoY Change	-1049.81%	-80.38%	-65.51%
FREE CASH FLOW
Cash From Operating Activities	-$700.1K	-$1.224M	-$3.374M
Capital Expenditures		$4.520K	$4.521K
Free Cash Flow		-$1.229M	-$3.379M
YoY Change		-26.4%	-24.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1405785	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1414848	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1938353	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	432952	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6982836	usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.034	pure
CY2023	us-gaap	Open Tax Year OpenTaxYear	2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001 per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	4000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4742363
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2023	dei	Auditor Name AuditorName	Weinberg & Company, P.A.
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q3	us-gaap	Cash Cash	222720	usd
CY2022Q3	us-gaap	Cash Cash	746940	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1364504	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1414848	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	362866	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	436407	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1950090	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2598195	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4599	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2044	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3500	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3500	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	8099	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	5544	usd
CY2023Q3	us-gaap	Assets Assets	1958189	usd
CY2022Q3	us-gaap	Assets Assets	2603739	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2304207	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1328000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	467496	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	318505	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	823128	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	127781	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	748275	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9465921	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3320494	usd
CY2023Q3	arch	Interest Payable Noncurrent InterestPayableNoncurrent	0	usd
CY2022Q3	arch	Interest Payable Noncurrent InterestPayableNoncurrent	204575	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	459200	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3476048	usd
CY2023Q3	us-gaap	Liabilities Liabilities	9465921	usd
CY2022Q3	us-gaap	Liabilities Liabilities	6796542	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4689446
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4689446
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1252734
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1252734
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	4689	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1252	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54543188	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	50878718	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62055609	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55072773	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7507732	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4192803	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1958189	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2603739	usd
CY2023	us-gaap	Revenues Revenues	75724	usd
CY2022	us-gaap	Revenues Revenues	15652	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	78163	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	51489	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4371164	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4519636	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	670880	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1153333	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	5120207	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	5724458	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5044483	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5708806	usd
CY2023	us-gaap	Interest Expense InterestExpense	3096550	usd
CY2022	us-gaap	Interest Expense InterestExpense	567048	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1158197	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5275854	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.4
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	3074115
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1199575
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4192803	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6982836	usd
CY2023	arch	Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts	2209840	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	718918	usd
CY2023	arch	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	49277	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	249555	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7507732	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1025674	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5275854	usd
CY2022	arch	Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts	1609141	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	499584	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4192803	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6982836	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5275854	usd
CY2023	us-gaap	Depreciation Depreciation	1966	usd
CY2022	us-gaap	Depreciation Depreciation	3196	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	249555	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	499583	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1158197	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1000000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	248073	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	2310860	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	302049	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-50344	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	569156	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-421091	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-225124	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	976207	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	846869	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	659690	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	265000	usd
CY2023	arch	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	97104	usd
CY2022	arch	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-959	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3374216	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4456075	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4521	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4521	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	350322	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	106257	usd
CY2023	arch	Proceeds From Convertible Notes Warrants And Common Stock Net Of Financing Costs ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts	0	usd
CY2022	arch	Proceeds From Convertible Notes Warrants And Common Stock Net Of Financing Costs ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts	3042633	usd
CY2023	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	995000	usd
CY2022	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	0	usd
CY2023	arch	Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts	2209839	usd
CY2022	arch	Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2854517	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2936376	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-524220	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1519699	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	746940	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2266639	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222720	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	746940	usd
CY2023	arch	Short Term Loan Issued ShortTermLoanIssued	347550	usd
CY2022	arch	Short Term Loan Issued ShortTermLoanIssued	354190	usd
CY2022	arch	Issuance Of Restricted Stock IssuanceOfRestrictedStock	8959	usd
CY2023	arch	Debt Conversion Converted Debt Amount DebtConversionConvertedDebtAmount	0	usd
CY2022	arch	Debt Conversion Converted Debt Amount DebtConversionConvertedDebtAmount	699781	usd
CY2023	arch	Issuance Of Restricted Stock For Services IssuanceOfRestrictedStockForServices	0	usd
CY2022	arch	Issuance Of Restricted Stock For Services IssuanceOfRestrictedStockForServices	30840	usd
CY2023	arch	Unpaid Issuance Costs In Accounts Payable UnpaidIssuanceCostsInAccountsPayable	110576	usd
CY2022	arch	Unpaid Issuance Costs In Accounts Payable UnpaidIssuanceCostsInAccountsPayable	73048	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6982836	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3374216	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.</p>
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	248073	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Concentration of Credit Risk</span></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash. </p>
CY2023Q3	arch	Operating Lease Monthly Rent Payment Obligation OperatingLeaseMonthlyRentPaymentObligation	3500	usd
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Derivative Liabilities</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, <i>Derivatives and Hedging</i> (“<i>ASC 815</i>”)<i>.</i> Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27124890
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1557530
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17607094	usd
CY2023Q3	arch	Reclassification Of Exchanged Notes Included In Notes Payable To Unsecured Convertible Notes ReclassificationOfExchangedNotesIncludedInNotesPayableToUnsecuredConvertibleNotes	699781	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	40969	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9063	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1323535	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1364504	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1427946	usd
CY2023Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1531	usd
CY2022Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2616	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	746143	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	162191	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15631061	usd
CY2023Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	51463	usd
CY2022Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	70805	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17607094	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15631061	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12905738	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11485524	usd
CY2023Q3	arch	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	1396415	usd
CY2022Q3	arch	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	1535736	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1014466	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	946246	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1491338	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16900	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0024	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0365	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.181	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0016	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0023	pure
CY2023	arch	Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Of Derivative Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent	0.0348	pure
CY2022	arch	Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Of Derivative Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent	0.0398	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0114	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2456	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0916	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1976000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	483000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	124495
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M9D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	140151	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6625
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	32494
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	70
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	98626
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	52
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y5M15D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	24500
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	21001
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	68
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102125
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	82940
CY2023	arch	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	44
CY2023	arch	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P4Y10M20D
CY2023	arch	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	102125
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	38
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.868	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.985	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.015	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.035	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.028	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.038	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.04	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	19.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	18
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	19.9
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18

Files In Submission

Name	View Source	Status
0001437749-24-004234-index-headers.html	Edgar Link	pending
0001437749-24-004234-index.html	Edgar Link	pending
0001437749-24-004234.txt	Edgar Link	pending
0001437749-24-004234-xbrl.zip	Edgar Link	pending
arch-20230930.xsd	Edgar Link	pending
arch-20230930_def.xml	Edgar Link	unprocessable
arch-20230930_lab.xml	Edgar Link	unprocessable
arch20230930_10k.htm	Edgar Link	pending
ex_608742.htm	Edgar Link	pending
ex_608743.htm	Edgar Link	pending
ex_608744.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
arch20230930_10k_htm.xml	Edgar Link	completed
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arch-20230930_cal.xml	Edgar Link	unprocessable
arch-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2024 Q1 Form 10-K Financial Statement

#000143774924004234 Filed on February 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2024 Q1 Form 10-K Financial Statement

#000143774924004234 Filed on February 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth